Definition and epidemiology
Anxiety disorders encompass generalized anxiety disorder (GAD), panic disorder, social anxiety disorder, specific phobias, and separation anxiety disorder, unified by excessive fear or anxiety and related behavioral disturbances that are out of proportion to actual threat.
- Lifetime prevalence of any anxiety disorder is approximately 15-20%, making it the most common class of psychiatric illness.
- GAD has a lifetime prevalence of roughly 5-6%.
- Female-to-male ratio is approximately 2:1 across most anxiety disorders.
- Typical age of onset is in the 20s-30s for GAD, though onset can occur across the lifespan; social phobia and specific phobias often begin in childhood or adolescence.
- Anxiety disorders are highly comorbid with major depressive disorder, substance use disorders, and other anxiety disorders.
- GAD requires excessive worry most days for at least 6 months plus 3 associated somatic/cognitive symptoms.
- Always rule out hyperthyroidism, pheochromocytoma, and substance use before diagnosing primary anxiety disorder.
- First-line treatment is CBT and/or SSRI/SNRI, not benzodiazepines.
- SSRIs/SNRIs carry an FDA black box warning for increased suicidality risk in patients under 25.
- Benzodiazepines are for short-term or breakthrough use only due to dependence risk.
- Buspirone is a non-habit-forming adjunct/alternative for GAD.
- Beta-blockers help situational performance anxiety by blunting somatic symptoms, not the underlying worry.
- GAD-7 is the standard primary care screening tool.
Etiology and risk factors
Anxiety arises from a combination of genetic predisposition, neurobiological dysregulation, and environmental stressors.
- Genetic factors: heritability estimated around 30-40%; family history of anxiety or mood disorders increases risk.
- Temperament: behavioral inhibition and neuroticism in childhood predict later anxiety.
- Environmental stressors: childhood adversity, trauma, chronic stress, major life transitions.
- Medical conditions that mimic or worsen anxiety: hyperthyroidism, pheochromocytoma, cardiac arrhythmias, COPD/asthma exacerbations, hypoglycemia.
- Substance-related: caffeine, stimulants, and withdrawal from alcohol, benzodiazepines, or opioids can precipitate anxiety symptoms.
- Psychosocial: low social support, female sex, and comorbid chronic illness increase risk.
Always rule out an organic or substance-induced cause before diagnosing a primary anxiety disorder, especially in a patient with new-onset symptoms after age 35 or with abnormal vital signs.
Pathophysiology
Anxiety involves dysregulated fear-processing circuitry rather than a single lesion or deficiency.
- The amygdala shows hyperactivity, driving exaggerated threat detection and fear response.
- The prefrontal cortex (particularly ventromedial regions) shows reduced top-down inhibitory control over the amygdala.
- Neurotransmitter systems implicated include serotonin, norepinephrine, and GABA; reduced GABAergic inhibition and noradrenergic excess contribute to physiologic arousal.
- The HPA axis is often dysregulated, with altered cortisol responses to stress.
- Autonomic hyperarousal (sympathetic activation) produces the somatic symptoms: tachycardia, diaphoresis, tremor, and GI upset.
This circuit-based model explains why both pharmacologic agents (modulating serotonin/norepinephrine/GABA) and psychotherapy (reshaping cortical appraisal of threat) are effective.
Clinical features
Core feature across anxiety disorders is excessive fear/worry with associated physical and cognitive symptoms.
GAD (DSM-5 core criteria)
- Excessive anxiety and worry about multiple events/activities, most days, for at least 6 months.
- Difficulty controlling the worry.
- At least 3 of: restlessness, easy fatigability, difficulty concentrating, irritability, muscle tension, sleep disturbance (only 1 required in children).
Associated somatic symptoms
- Tachycardia, palpitations, tremor, sweating, GI distress, headache, muscle tension.
Other anxiety-spectrum presentations (for differentiation)
- Panic disorder: discrete, recurrent panic attacks with fear of recurrence.
- Social anxiety disorder: fear specific to social/performance situations.
- Specific phobia: fear tied to a discrete object or situation.
Symptoms must cause clinically significant distress or functional impairment and not be better explained by a substance, medical condition, or another mental disorder.
Diagnosis
Diagnosis is clinical, based on history and exclusion of organic causes; no laboratory test confirms anxiety disorder.
- History and DSM-5 criteria are the diagnostic standard.
- Screening tools: GAD-7 questionnaire is widely used in primary care; score correlates with severity.
- Initial workup to exclude organic mimics: TSH, CBC, basic metabolic panel, ECG if cardiac symptoms, urine toxicology if substance use suspected, and consideration of pheochromocytoma (plasma free metanephrines) only if clinical suspicion is high (paroxysmal hypertension, headache, diaphoresis).
- Rule out substance/medication-induced anxiety disorder (caffeine, stimulants, corticosteroids, thyroid hormone, withdrawal states).
- Diagnosis requires symptoms not attributable to another mental disorder (e.g., not solely during a major depressive episode).
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Hyperthyroidism | Weight loss, heat intolerance, tachycardia, abnormal TSH |
| Pheochromocytoma | Paroxysmal hypertension, episodic headache/diaphoresis |
| Panic disorder | Discrete, abrupt panic attacks rather than chronic worry |
| Major depressive disorder | Prominent anhedonia, low mood; often comorbid with anxiety |
| Substance intoxication/withdrawal | Temporal link to caffeine, stimulants, alcohol/benzodiazepine withdrawal |
| Cardiac arrhythmia | Palpitations with objective ECG abnormality |
| PTSD | Symptoms follow identifiable trauma, with re-experiencing/avoidance |
| Obsessive-compulsive disorder | Intrusive thoughts with compulsions, not generalized worry |
Management
Management combines psychotherapy and pharmacotherapy; choice depends on severity, patient preference, and access.
First-line
- Cognitive behavioral therapy (CBT): strong evidence across all anxiety disorders; often preferred for mild-moderate disease or patient preference against medication.
- SSRIs (e.g., sertraline, escitalopram, paroxetine) or SNRIs (venlafaxine, duloxetine): first-line pharmacotherapy, effective for GAD, panic disorder, and social anxiety disorder.
- Combination of CBT plus medication is often used for moderate-severe disease.
- Black box warning: the FDA requires a boxed warning on all SSRIs and SNRIs for increased risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24, particularly during the first few months of treatment or after dose changes. Close monitoring for worsening depression, agitation, or emergent suicidality is recommended in this age group regardless of the indication being treated.
Second-line / adjunctive
- Buspirone: non-benzodiazepine anxiolytic, useful as adjunct or alternative in GAD; lacks abuse potential.
- Pregabalin: alternative in GAD, more commonly used in European guidelines.
- Beta-blockers (e.g., propranolol): useful for performance-related situational anxiety (social phobia, performance anxiety) to blunt somatic symptoms.
Benzodiazepines
- Effective and fast-acting but reserved for short-term use or acute severe anxiety/panic due to risk of tolerance, dependence, and withdrawal; avoided as monotherapy or long-term treatment, especially in older adults and those with substance use history.
General principles
- Lifestyle measures: reduce caffeine/stimulant intake, regular exercise, sleep hygiene.
- Guideline consensus (APA, NICE, WHO mhGAP) uniformly supports CBT and SSRIs/SNRIs as first-line; NICE additionally emphasizes a stepped-care model, starting with low-intensity psychoeducation/self-help before escalating to high-intensity CBT or medication.
Complications and prognosis
Untreated anxiety disorders tend to be chronic and relapsing but are generally not life-threatening in themselves.
- Functional impairment: occupational, academic, and relationship difficulties.
- Comorbid depression: common and worsens prognosis; screen for suicidal ideation.
- Substance use disorder: self-medication with alcohol or sedatives is a recognized complication.
- Chronic course: GAD often becomes a chronic, waxing-and-waning condition without treatment.
- Prognosis: with CBT and/or pharmacotherapy, most patients achieve significant symptom improvement; relapse is common after medication discontinuation, so gradual tapering and continued psychotherapy skills are recommended.
GAD-7 criteria mnemonic 'WATCHERS': Worry (excessive), Anxiety hard to control, Tension (muscle), Concentration difficulty, Hyperarousal/restlessness, Energy loss (fatigue), Rest disturbance (sleep), Snappish (irritability).
Practice questions
1. A 29-year-old woman presents with 8 months of excessive worry about her job, finances, and family health. She reports muscle tension, poor concentration, and difficulty falling asleep. Physical exam and TSH are normal. Which of the following is the most appropriate first-line treatment?
2. A 45-year-old man with generalized anxiety disorder has a history of alcohol use disorder in remission. He requests medication for his anxiety. Which agent is most appropriate given his history, due to its lack of abuse potential?
3. A 34-year-old woman reports palpitations, excessive sweating, and anxiety that occur in episodes, sometimes associated with significant blood pressure spikes and headache. Baseline anxiety screening is otherwise unremarkable between episodes. Which test should be obtained before diagnosing a primary anxiety disorder?
Frequently asked questions
What causes anxiety disorder?
Anxiety disorder results from a combination of genetic predisposition, dysregulated fear circuitry involving the amygdala and prefrontal cortex, and environmental stressors such as trauma or chronic stress. Neurotransmitter systems including serotonin, norepinephrine, and GABA are involved. Medical conditions like hyperthyroidism and substances like caffeine or stimulants can also trigger or worsen anxiety symptoms, so these should always be excluded first.
What are the first symptoms of anxiety?
Early symptoms typically include persistent worry that feels hard to control, along with restlessness, muscle tension, fatigue, trouble concentrating, irritability, and sleep disturbance. Physical symptoms like a racing heart, sweating, and GI upset often accompany the psychological symptoms. Symptoms become diagnostically significant when they persist most days for six months and impair daily functioning.
How is anxiety diagnosed?
Anxiety disorder is diagnosed clinically using DSM-5 criteria based on history, often supported by a screening tool like the GAD-7 questionnaire. There is no blood test that confirms the diagnosis, but basic labs such as TSH and sometimes an ECG are used to exclude medical mimics like thyroid disease or arrhythmia. The diagnosis requires that symptoms are not better explained by a substance or another medical or psychiatric condition.
Is anxiety disorder curable?
Anxiety disorder is highly treatable but is usually considered a manageable, chronic-relapsing condition rather than one that is permanently cured. Most patients achieve substantial, lasting improvement with cognitive behavioral therapy and/or medication, and many can eventually taper off medication while maintaining therapy skills. Relapse is common, especially if treatment is stopped abruptly, so ongoing monitoring is recommended.
Anxiety vs panic disorder — what is the difference?
Generalized anxiety disorder involves chronic, pervasive worry about multiple areas of life occurring most days for at least six months, whereas panic disorder is defined by discrete, abrupt panic attacks with intense fear and physical symptoms that peak within minutes. A person with panic disorder also develops persistent worry about having another attack, while GAD worry is broader and not centered on attacks themselves. Both can coexist in the same patient.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F41.9
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.